BMC Pharmacology

Table 1 IC₅₀ Values for Chemotherapy Drugs

From: Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells

	Brca1^+/+ MMECs	Brca1^-/- MMECs	p-value
DNA-damaging Drugs	(μM)	(μM)
Doxorubicin	0.06 ± 0.02	0.04 ± 0.02	0.3
Cisplatin	0.8 ± 0.1	0.06 ± 0.02	0.001**
Carboplatin	10 ± 4	6 ± 2	0.03*
Oxaliplatin	5 ± 1	2 ± 1	0.04*
Taxanes
Paclitaxel	0.4 ± 0.3	0.08 ± 0.06	0.1
Docetaxel	0.001 ± 0.0009	0.002 ± 0.002	0.5
Antimetabolites
5-FU	0.8 ± 0.5	4 ± 0.9	0.004**
Gemcitabine	0.05 ± 0.02	0.002 ± 0.	0.02*

**Highly statistically significant (p < 0.01)
*Statistically significant (p < 0.05)

Back to article page